Joshua R. Disbrow - 19 Dec 2022 Form 4 Insider Report for AYTU BIOPHARMA, INC (AYTU)

Role: Chief Executive Officer, Director
Signature: /s/ Mark Oki as attorney-in-fact for Joshua R. Disbrow
Issuer symbol: AYTU
Transactions as of: 19 Dec 2022
Net transactions value: +$25,047
Form type: 4
Filing time: 21 Dec 2022, 08:17:07 UTC
Previous filing: 28 Nov 2022
Next filing: 23 Dec 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AYTU	Common Stock	Purchase	$25,047	+112,371	+10%	$0.2229	1,231,877	19 Dec 2022	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The purchase price reported above is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.213 to $0.23, inclusive. The reporting person undertakes to provide to AYTU Biopharma, Inc., any security holder of AYTU Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

Content

The purchase price reported above is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.213 to $0.23, inclusive. The reporting person undertakes to provide to AYTU Biopharma, Inc., any security holder of AYTU Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

Remarks:

Exhibit 24.1 Power of Attorney